Caseware UK (AP4) 2023.0.135 2023.0.135 2023-06-302023-06-30true2022-07-19No description of principal activity3falsetruefalse 14244134 2022-07-18 14244134 2022-07-19 2023-06-30 14244134 2021-07-19 2022-07-18 14244134 2023-06-30 14244134 c:Director3 2022-07-19 2023-06-30 14244134 d:CurrentFinancialInstruments 2023-06-30 14244134 d:CurrentFinancialInstruments d:WithinOneYear 2023-06-30 14244134 d:ShareCapital 2023-06-30 14244134 d:RetainedEarningsAccumulatedLosses 2023-06-30 14244134 c:EntityHasNeverTraded 2022-07-19 2023-06-30 14244134 c:FRS102 2022-07-19 2023-06-30 14244134 c:AuditExempt-NoAccountantsReport 2022-07-19 2023-06-30 14244134 c:FullAccounts 2022-07-19 2023-06-30 14244134 c:PrivateLimitedCompanyLtd 2022-07-19 2023-06-30 14244134 e:PoundSterling 2022-07-19 2023-06-30 iso4217:GBP xbrli:pure

Registered number: 14244134









MIRAYA PHARMA LIMITED







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE PERIOD ENDED 30 JUNE 2023

 
MIRAYA PHARMA LIMITED
REGISTERED NUMBER: 14244134

STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2023

2023
Note
£

  

Current assets
  

Debtors: amounts falling due within one year
  
98,318

Cash at bank and in hand
  
320,070

  
418,388

Creditors: amounts falling due within one year
  
(19,188)

Net current assets
  
 
 
399,200

Total assets less current liabilities
  
399,200

  

Net assets
  
399,200


Capital and reserves
  

Called up share capital 
  
400,100

Profit and loss account
  
(900)

  
399,200


For the period ended 30 June 2023 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006.

Members have not required the Company to obtain an audit for the period in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The Company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the income statement in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 11 September 2024.




Mr Shahil Soni
Director

Page 1

 
MIRAYA PHARMA LIMITED
REGISTERED NUMBER: 14244134
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 30 JUNE 2023

The notes on pages 3 to 4 form part of these financial statements.

Page 2

 
MIRAYA PHARMA LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 JUNE 2023

1.


General information

Miraya Pharma Limited is a private company, limited by share capital, incorporated in England and
Wales under registration number 14244134. The address of the registered office is Zeeta House Third Floor 200 Upper Richmond Road, Putney, London, SW15 2SH.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies.

 
2.2

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.3

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


Employees




The average monthly number of employees, including the directors, during the period was as follows:


        2023
            No.






Employees
3


4.


Debtors

2023
£


Other debtors
98,318

98,318

Page 3

 
MIRAYA PHARMA LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 JUNE 2023

4.Debtors (continued)



5.


Cash and cash equivalents

2023
£

Cash at bank and in hand
320,070

320,070



6.


Creditors: Amounts falling due within one year

2023
£

Directors loan account
18,288

Accruals
900

19,188



7.


Controlling party

The company was under the control of Mr Shahil Soni (50% share) and Mrs Minal Jani (50% share) by virtue of the fact that between them they own 100% of the issued ordinary share capital of the company.

 
Page 4